Sort   by:  
 Page size 
UnknownFive-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.
Not available
S-EPMC5795709 | biostudies-literature
UnknownLonger Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma.
Not available
S-EPMC6286159 | biostudies-literature
UnknownEfficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.
Not available
S-EPMC5791828 | biostudies-literature
UnknownInterferon alpha for the adjuvant treatment of cutaneous melanoma.
Not available
S-EPMC10773707 | biostudies-literature
UnknownClinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab.
Not available
S-EPMC5215225 | biostudies-literature
UnknownInvestigating the Retained Inhibitory Effect of Cobimetinib against p.P124L Mutated MEK1: A Combined Liquid Biopsy and in Silico Approach.
Not available
S-EPMC9454486 | biostudies-literature
UnknownThe immune cell landscape of metastatic uveal melanoma correlates with overall survival.
Not available
S-EPMC8097926 | biostudies-literature
UnknownEffect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020.
Not available
S-EPMC12083276 | biostudies-literature
UnknownGenetic features of metachronous esophageal cancer developed in Hodgkin's lymphoma or breast cancer long-term survivors: an exploratory study.
Not available
S-EPMC4303414 | biostudies-literature
UnknownA gene expression signature associated with survival in metastatic melanoma.
Not available
S-EPMC1697826 | biostudies-literature
Sort   by:  
 Page size